Anti-platelet Therapy for Stroke Prevention in Atrial Fibrillation and Severe Chronic Kidney Disease
There is currently insufficient evidence to recommend single or dual antiplatelet therapy for stroke prevention in patients with atrial fibrillation and stages 4/5 or 5D CKD even when OAC is undesirable. Bleeding risk appears to be increased and there is no evidence for efficacy. It is recommended that their combined use with OAC should be avoided in severe CKD except in specific situations (e.g. recent coronary stent).
Curr Opin Nephrol Hypertens. 2018;27(6):420-425. © 2018 Lippincott Williams & Wilkins